8-KItem 2.02 · Results of OperationsItem 8.01 · Other EventsItem 9.01 · Financial Statements
QUEST DIAGNOSTICS INC (DGX)

Quest Diagnostics ($DGX) filed a Form 8-K on Feb 10, 2026 attaching a press release with Q4 & FY 2025…

Filed with the SEC on · Summarized by InvestorsBot

Quest Diagnostics ($DGX) filed a Form 8-K on Feb 10, 2026 attaching a press release with Q4 & FY 2025 results for the quarter and full year ended Dec 31, 2025 (Exhibit 99.1). 📊 #earnings #healthcare

Quest Diagnostics ($DGX) 8-K (Feb 10, 2026) also includes a press release announcing an increase in its quarterly dividend and an increase to its share repurchase authorization (Exhibit 99.2). 🔁💵 #dividends #buybacks

The Form 8-K was signed Feb 10, 2026 by Sean D. Mersten, VP & Corporate Secretary; exhibits filed include 99.1, 99.2 and the Inline XBRL cover page (Exhibit 104). 🖋️ $DGX #SECfiling #corporategovernance

Read the original filing on SEC EDGAR

Get summaries like this in your inbox every morning

Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.

Subscribe free

More from QUEST DIAGNOSTICS INC

Quest Diagnostics Reports Q2 Growth and Raises 2026 Guidance

8-K · July 23, 2026

Quest Diagnostics ($DGX) filed a Form 8‑K on Mar 12, 2026 — Item 9.01 lists exhibits: Press release dated…

8-K · March 12, 2026

Quest Diagnostics ($DGX) disclosed (Reg FD) that Mr.

8-K · March 12, 2026

On Mar 9, 2026 Quest Diagnostics ($DGX) added Timothy Wentworth, former CEO of Walgreens Boots Alliance,…

8-K · March 12, 2026

Quest Diagnostics ($DGX) Board of Directors authorized an additional $1.0B of common stock repurchases…

8-K · February 10, 2026

Quest Diagnostics ($DGX) filed an 8‑K (Item 2.02) on Feb 10, 2026 announcing Q4 and full‑year results for…

8-K · February 10, 2026